162 related articles for article (PubMed ID: 29893546)
1. Lack of Effect of Sodium Benzoate at Reported Clinical Therapeutic Concentration on d-Alanine Metabolism in Dogs.
Popiolek M; Tierney B; Steyn SJ; DeVivo M
ACS Chem Neurosci; 2018 Nov; 9(11):2832-2837. PubMed ID: 29893546
[TBL] [Abstract][Full Text] [Related]
2. Benzoate, a D-amino acid oxidase inhibitor, for the treatment of early-phase Alzheimer disease: a randomized, double-blind, placebo-controlled trial.
Lin CH; Chen PK; Chang YC; Chuo LJ; Chen YS; Tsai GE; Lane HY
Biol Psychiatry; 2014 May; 75(9):678-85. PubMed ID: 24074637
[TBL] [Abstract][Full Text] [Related]
3. Determination of D-serine and D-alanine Tissue Levels in the Prefrontal Cortex and Hippocampus of Rats After a Single Dose of Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, with Potential Antipsychotic and Antidepressant Properties.
Huang CC; Wei IH; Yang HT; Lane HY
Neurochem Res; 2023 Jul; 48(7):2066-2076. PubMed ID: 36786942
[TBL] [Abstract][Full Text] [Related]
4. Add-on treatment of benzoate for schizophrenia: a randomized, double-blind, placebo-controlled trial of D-amino acid oxidase inhibitor.
Lane HY; Lin CH; Green MF; Hellemann G; Huang CC; Chen PW; Tun R; Chang YC; Tsai GE
JAMA Psychiatry; 2013 Dec; 70(12):1267-75. PubMed ID: 24089054
[TBL] [Abstract][Full Text] [Related]
5. Sodium Benzoate, a D-Amino Acid Oxidase Inhibitor, Added to Clozapine for the Treatment of Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial.
Lin CH; Lin CH; Chang YC; Huang YJ; Chen PW; Yang HT; Lane HY
Biol Psychiatry; 2018 Sep; 84(6):422-432. PubMed ID: 29397899
[TBL] [Abstract][Full Text] [Related]
6. Assessment of the Target Engagement and D-Serine Biomarker Profiles of the D-Amino Acid Oxidase Inhibitors Sodium Benzoate and PGM030756.
Howley E; Bestwick M; Fradley R; Harrison H; Leveridge M; Okada K; Fieldhouse C; Farnaby W; Canning H; Sykes AP; Merchant K; Hazel K; Kerr C; Kinsella N; Walsh L; Livermore DG; Hoffman I; Ellery J; Mitchell P; Patel T; Carlton M; Barnes M; Miller DJ
Neurochem Res; 2017 Nov; 42(11):3279-3288. PubMed ID: 28780732
[TBL] [Abstract][Full Text] [Related]
7. Novel Treatment for the Most Resistant Schizophrenia: Dual Activation of NMDA Receptor and Antioxidant.
Lin CH; Chen YM; Lane HY
Curr Drug Targets; 2020; 21(6):610-615. PubMed ID: 31660823
[TBL] [Abstract][Full Text] [Related]
8. Oral administration of D-alanine in monkeys robustly increases plasma and cerebrospinal fluid levels but experimental D-amino acid oxidase inhibitors had minimal effect.
Rojas C; Alt J; Ator NA; Wilmoth H; Rais R; Hin N; DeVivo M; Popiolek M; Tsukamoto T; Slusher BS
J Psychopharmacol; 2016 Sep; 30(9):887-95. PubMed ID: 27287825
[TBL] [Abstract][Full Text] [Related]
9. Modulating NMDA Receptor Function with D-Amino Acid Oxidase Inhibitors: Understanding Functional Activity in PCP-Treated Mouse Model.
Sershen H; Hashim A; Dunlop DS; Suckow RF; Cooper TB; Javitt DC
Neurochem Res; 2016 Feb; 41(1-2):398-408. PubMed ID: 26857796
[TBL] [Abstract][Full Text] [Related]
10. Adjunctive sarcosine plus benzoate improved cognitive function in chronic schizophrenia patients with constant clinical symptoms: A randomised, double-blind, placebo-controlled trial.
Lin CY; Liang SY; Chang YC; Ting SY; Kao CL; Wu YH; Tsai GE; Lane HY
World J Biol Psychiatry; 2017 Aug; 18(5):357-368. PubMed ID: 26691576
[TBL] [Abstract][Full Text] [Related]
11. Recent advances in the discovery of D-amino acid oxidase inhibitors and their therapeutic utility in schizophrenia.
Ferraris DV; Tsukamoto T
Curr Pharm Des; 2011; 17(2):103-11. PubMed ID: 21361869
[TBL] [Abstract][Full Text] [Related]
12. Precision Medicine of Sodium Benzoate for the Treatment of Behavioral and Psychological Symptoms of Dementia (BPSD).
Lin CH; Yang HT; Chen PK; Wang SH; Lane HY
Neuropsychiatr Dis Treat; 2020; 16():509-518. PubMed ID: 32110025
[TBL] [Abstract][Full Text] [Related]
13. Effects of sodium benzoate on pre-pulse inhibition deficits and hyperlocomotion in mice after administration of phencyclidine.
Matsuura A; Fujita Y; Iyo M; Hashimoto K
Acta Neuropsychiatr; 2015 Jun; 27(3):159-67. PubMed ID: 25648314
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of Sodium Benzoate, a d-Amino Acid Oxidase (DAAO) Inhibitor, in Healthy Subjects: A Phase I, Open-label Study.
Lin YS; Mao WC; Yao NT; Tsai GE
Clin Ther; 2022 Oct; 44(10):1326-1335. PubMed ID: 36104267
[TBL] [Abstract][Full Text] [Related]
15. Sodium benzoate for the treatment of behavioral and psychological symptoms of dementia (BPSD): A randomized, double-blind, placebo-controlled, 6-week trial.
Lin CH; Chen PK; Wang SH; Lane HY
J Psychopharmacol; 2019 Aug; 33(8):1030-1033. PubMed ID: 31113277
[TBL] [Abstract][Full Text] [Related]
16. Drug discovery strategies and the preclinical development of D-amino-acid oxidase inhibitors as antipsychotic therapies.
Szilágyi B; Ferenczy GG; Keserű GM
Expert Opin Drug Discov; 2018 Oct; 13(10):973-982. PubMed ID: 30220232
[TBL] [Abstract][Full Text] [Related]
17. D-dopa is unidirectionally converted to L-dopa by D-amino acid oxidase, followed by dopa transaminase.
Wu M; Zhou XJ; Konno R; Wang YX
Clin Exp Pharmacol Physiol; 2006 Nov; 33(11):1042-6. PubMed ID: 17042912
[TBL] [Abstract][Full Text] [Related]
18. Brain Activity of Benzoate, a D-Amino Acid Oxidase Inhibitor, in Patients With Mild Cognitive Impairment in a Randomized, Double-Blind, Placebo Controlled Clinical Trial.
Lane HY; Tu CH; Lin WC; Lin CH
Int J Neuropsychopharmacol; 2021 May; 24(5):392-399. PubMed ID: 33406269
[TBL] [Abstract][Full Text] [Related]
19. Targeting D-Amino Acid Oxidase (DAAO) for the Treatment of Schizophrenia: Rationale and Current Status of Research.
Kuo CY; Lin CH; Lane HY
CNS Drugs; 2022 Nov; 36(11):1143-1153. PubMed ID: 36194364
[TBL] [Abstract][Full Text] [Related]
20. Inhibitory effects of benzoate on chiral inversion and clearance of N(G)-nitro-arginine in conscious rats.
Yan-Fei X; Xiang-Jun Z; Jie L; Yong-Xiang W
Drug Metab Dispos; 2007 Mar; 35(3):331-4. PubMed ID: 17172314
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
